This study will confirm the efficacy and safety in the clinical setting after the launch of the GOREĀ® VIABAHNĀ® stent graft (hereafter referred to as "Viabahn") for the treatment of patients with stenosis or occlusion at the venous anastomosis of synthetic arteriovenous access graft.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Number of Subjects With Loss of Primary Patency of Target Lesion
Timeframe: up to 2 years
Number of Subjects With Loss of Secondary Patency of Target Lesion
Timeframe: up to 2 years
Number of Subjects With Loss of Primary Patency of Vascular Access Circuit
Timeframe: up to 2 years
Number of Subjects With Loss of Secondary Patency of Vascular Access Circuit
Timeframe: up to 2 years
Mean Cumulative Number of Re-treatment Per Target Lesion
Timeframe: at 24 months
Number of Subjects Achieving Technical Success
Timeframe: Day 1
Number of Subjects Achieving Clinical Success
Timeframe: Day 1 to Month 1 follow up
Number of Subjects Experiencing Device and Procedure-related Adverse Events
Timeframe: Day 1 to Month 1 follow up
Number of Subjects Experiencing Device Defects
Timeframe: Day 1 to Month 1 follow up